Nalaganje...

Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer

In advanced lung cancer, epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) have extraordinary clinical efficacy. However, their usefulness is severely compromised by drug resistance mediated by various mechanisms, the most important of which is the secondary EGFR T790M mutation. The mut...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Oncol
Main Authors: Li, Hongjian, Tong, Christy Wing-Sum, Leung, Yee, Wong, Man-Hon, To, Kenneth Kin-Wah, Leung, Kwong-Sak
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2017
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5712561/
https://ncbi.nlm.nih.gov/pubmed/29238696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00288
Oznake: Označite
Brez oznak, prvi označite!